Cardiotoxic manifestations of chemotherapy of malignant tumors: pathogenesis and diagnosis

Authors

  • T. YU. UGLYAR I. Horbachevsky Ternopil National Medical University Ternopil Regional Clinical Oncology Dispensary
  • O. S. KARASHIVSKA I. Horbachevsky Ternopil National Medical University Ternopil Regional Clinical Oncology Dispensary
  • L. V. NITEFOR I. Horbachevsky Ternopil National Medical University

DOI:

https://doi.org/10.11603/2414-4533.2023.3.14159

Keywords:

malignant tumors, cytostatics, cardiovascular insufficiency, chemotherapy, cardiotoxic effects

Abstract

The article provides an overview of modern international guidelines for chemotherapeutic treatment of cancer patients with cardiovascular pathology. An analysis of the cardiotoxic manifestations of cytostatics, which are used for chemotherapy of malignant tumors, was carried out. The areas of prevention of side complications of chemotherapeutic treatment on the cardiovascular system have been determined.

References

Brown, J. C., Winters-Stone, K., Lee, A., & Schmitz, K. H. (2012). Cancer, physical activity, and exercise. Comprehensive Physiology, 2(4), 2775–2809. https://doi.org/10.1002/cphy.c120005. DOI: https://doi.org/10.1002/cphy.c120005

Youlden, D.R., Cramb, S.M., Yip, C.H., & Baade, P.D. (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biology & Medicine, 11(2), 101–115. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005.

Ning, S., Wei, W., Li, J., Hou, B., Zhong, J., Xie, Y., Liu, H., Mo, X., Chen, J., & Zhang, L. (2018). Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. Journal of Cancer, 9(3), 494–501. https://doi.org/10.7150/jca.21562. DOI: https://doi.org/10.7150/jca.21562

Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., Krznaric, Z., Laird, B., Larsson, M., Laviano, A., Mühlebach, S., Muscaritoli, M., Oldervoll, L., Ravasco, P., Solheim, T., Strasser, F., … Preiser, J. C. (2017). ESPEN guidelines on nutrition in cancer patients. Clinical nutrition (Edinburgh, Scotland), 36(1), 11–48. https://doi.org/10.1016/j.clnu.2016.07.015. DOI: https://doi.org/10.1016/j.clnu.2016.07.015

Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4. DOI: https://doi.org/10.1186/s12885-018-4015-4

Koene, R. J., Prizment, A. E., Blaes, A., & Konety, S. H. (2016). Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation, 133(11), 1104–1114. https://doi.org/10.1161/CIRCULATIONAHA.115.020406. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.020406

Ather, S., Chan, W., Bozkurt, B., Aguilar, D., Ramasubbu, K., Zachariah, A. A., Wehrens, X. H., & Deswal, A. (2012). Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. 59 (11), 998-1005. https://doi.org/10.1016/j.jacc.2011.11.040. DOI: https://doi.org/10.1016/j.jacc.2011.11.040

Hasin, T., Gerber, Y., McNallan, S.M., Weston, S.A., Kushwaha, S.S., Nelson, T.J., Cerhan, J.R., & Roger, V.L. (2013). Patients with heart failure have an increased risk of incident cancer. Journal of the American College of Cardiology, 62(10), 881-886. https://doi.org/10.1016/j.jacc.2013.04.088. DOI: https://doi.org/10.1016/j.jacc.2013.04.088

Banke, A., Schou, M., Videbaek, L., Møller, J. E., Torp-Pedersen, C., Gustafsson, F., Dahl, J. S., Køber, L., Hildebrandt, P. R., & Gislason, G. H. (2016). Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. European Journal of Heart Failure, 18 (3), 260-266. https://doi.org/10.1002/ejhf.472. DOI: https://doi.org/10.1002/ejhf.472

Hasin, T., Gerber, Y., Weston, S. A., Jiang, R., Killian, J.M., Manemann, S. M., Cerhan, J.R., & Roger, V.L. (2016). Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. Journal of the American College of Cardiology, 68 (3), 265-271. https://doi.org/10.1016/j.jacc.2016.04.053. DOI: https://doi.org/10.1016/j.jacc.2016.04.053

Murphy K.T. (2016). The pathogenesis and treatment of cardiac atrophy in cancer cachexia. American journal of physiology. Heart and circulatory physiology, 310(4), H466–H477. https://doi.org/10.1152/ajpheart.00720.2015. DOI: https://doi.org/10.1152/ajpheart.00720.2015

Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., Köstler, W., Zöchbauer-Müller, S., Marosi, C., Kornek, G., Auerbach, L., Schneider, S., Parschalk, B., Scheithauer, W., Pirker, R., Drach, J., … Pacher, R. (2015). Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart (British Cardiac Society), 101(23), 1874–1880. https://doi.org/10.1136/heartjnl-2015-307848. DOI: https://doi.org/10.1136/heartjnl-2015-307848

Tuñón, J., Higueras, J., Tarín, N., Cristóbal, C., Lorenzo, Ó., Blanco-Colio, L., Martín-Ventura, J. L., Huelmos, A., Alonso, J., Aceña, Á., Pello, A., Carda, R., Asensio, D., Mahíllo-Fernández, I., López Bescós, L., Egido, J., & Farré, J. (2015). N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. PloS one, 10(6), e0126741. https://doi.org/10.1371/journal.pone.0126741. DOI: https://doi.org/10.1371/journal.pone.0126741

Meijers, W.C., Maglione, M., Bakker, S.J.L., Oberhuber, R., Kieneker, L. M., de Jong, S., Haubner, B. J., Nagengast, W. B., Lyon, A. R., van der Vegt, B., van Veldhuisen, D.J., Westenbrink, B.D., van der Meer, P., Silljé, H.H.W., & de Boer, R. A. (2018). Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 138(7), 678–691. https://doi.org/10.1161/CIRCULATIONAHA. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.030816

030816

Lok, S.I., Lok, D.J., van der Weide, P., Winkens, B., Bruggink-André de la Porte, P.W., Doevendans, P.A., de Weger, R.A., van der Meer, P., & de Jonge, N. (2014). Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 22(9), 391-395. https://doi.org/10.1007/s12471-014-0584-2. DOI: https://doi.org/10.1007/s12471-014-0584-2

Long, N.P., Lee, W.J., Huy, N.T., Lee, S.J., Park, J.H., & Kwon, S.W. (2016). Novel Biomarker Candidates for Colorectal Cancer Metastasis: A Meta-analysis of In Vitro Studies. Cancer informatics, 15(Suppl 4), 11-17. https://doi.org/10.4137/CIN.S40301. DOI: https://doi.org/10.4137/CIN.S40301

Zhou, J., Cheng, Y., Tang, L., Martinka, M., & Kalia, S. (2017). Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells. Oncotarget, 8 (12), 18712-18725. https://doi.org/10.18632/oncotarget.9409. DOI: https://doi.org/10.18632/oncotarget.9409

Peltier, J., Roperch, J.P., Audebert, S., Borg, J.P., & Camoin, L. (2016). Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family. Journal of Proteomics, 148, 139-148. https://doi.org/10.1016/j.jprot.2016.07.031. DOI: https://doi.org/10.1016/j.jprot.2016.07.031

Bode, J. G., Albrecht, U., Häussinger, D., Heinrich, P. C., & Schaper, F. (2012). Hepatic acute phase proteins-regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. European journal of cell biology, 91(6-7), 496-505. https://doi.org/10.1016/j.ejcb.2011.09.008. DOI: https://doi.org/10.1016/j.ejcb.2011.09.008

Surinova, S., Choi, M., Tao, S., Schüffler, P.J., Chang, C.Y., Clough, T., Vysloužil, K., Khoylou, M., Srovnal, J., Liu, Y., Matondo, M., Hüttenhain, R., Weisser, H., Buhmann, J.M., Hajdúch, M., Brenner, H., Vitek, O., & Aebersold, R. (2015). Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Molecular Medicine, 7 (9), 1166-1178. https://doi.org/10.15252/ DOI: https://doi.org/10.15252/emmm.201404873

emmm.201404873.

Limoge, M., Safina, A., Truskinovsky, A.M., Aljahdali, I., Zonneville, J., Gruevski, A., Arteaga, C.L., & Bakin, A.V. (2017). Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget, 8 (37), 61969-61981. https://doi.org/10.18632/oncotarget.18755. DOI: https://doi.org/10.18632/oncotarget.18755

Saito, N., Nishimura, H., & Kameoka, S. (2008). Clinical significance of fibronectin expression in colorectal cancer. Molecular Medicine Reports, 1 (1), 77-81. DOI: https://doi.org/10.3892/mmr.1.1.77

Van Cutsem, E., Hoff, P. M., Blum, J. L., Abt, M., & Osterwalder, B. (2002). Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Annals of oncology: Official Journal of the European Society for Medical Oncology, 13 (3), 484-485. https://doi.org/ DOI: https://doi.org/10.1093/annonc/mdf108

1093/annonc/mdf108.

Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen, D.L. (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treatment Reviews, 39 (8), 974-984. https://doi.org/10.1016/j.ctrv.2013.03.005. DOI: https://doi.org/10.1016/j.ctrv.2013.03.005

Layoun, M.E., Wickramasinghe, C.D., Peralta, M.V., & Yang, E.H. (2016). Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Current Oncology Reports, 18 (6), 35. https://doi.org/10.1007/s11912-016-0521-1. DOI: https://doi.org/10.1007/s11912-016-0521-1

Jensen, S.A., Hasbak, P., Mortensen, J., & Sørensen, J.B. (2010). Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28 (36), 5280-5286. https://doi.org/10.1200/JCO.2009.27.3953. DOI: https://doi.org/10.1200/JCO.2009.27.3953

Raber, I., Warack, S., Kanduri, J., Pribish, A., Godishala, A., Abovich, A., Orbite, A., Dommaraju, S., Frazer, M., Peters, M.L., & Asnani, A. (2020). Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study. The Oncologist, 25 (3), e606-e609. https://doi.org/10.1634/theoncologist.2019-0762. DOI: https://doi.org/10.1634/theoncologist.2019-0762

McAndrew, E.N., Jassal, D.S., Goldenberg, B.A., & Kim, C.A. (2021). Capecitabine-mediated heart failure in colorectal cancer: a case series. European Heart Journal. Case Reports, 5 (3), ytab079. https://doi.org/10.1093/ehjcr/ytab079 DOI: https://doi.org/10.1093/ehjcr/ytab079

Raber, I., Frazer, M.B., Zerillo, J.A., & Asnani, A. (2020). Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants. JACC. CardioOncology, 2 (2), 329-332. https://doi.org/ DOI: https://doi.org/10.1016/j.jaccao.2020.04.005

1016/j.jaccao.2020.04.005. DOI: https://doi.org/10.1088/1475-7516/2020/04/005

Kelly, C., Bhuva, N., Harrison, M., Buckley, A., & Saunders, M. (2013). Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. European Journal of Cancer, 49 (10), 2303-2310. https://doi.org/10.1016/j.ejca.2013.03.004. DOI: https://doi.org/10.1016/j.ejca.2013.03.004

Maughan, T.S., James, R.D., Kerr, D.J., Ledermann, J.A., McArdle, C., Seymour, M.T., Cohen, D., Hopwood, P., Johnston, C., Stephens, R.J., & British MRC Colorectal Cancer Wor­king Party (2002). Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet, 359 (9317), 1555-1563. https://doi.org/10.1016/s0140-6736(02)08514-8. DOI: https://doi.org/10.1016/S0140-6736(02)08514-8

Pareek, N., Cevallos, J., Moliner, P., Shah, M., Tan, L.L., Chambers, V., Baksi, A.J., Khattar, R.S., Sharma, R., Rosen, S.D., & Lyon, A.R. (2018). Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. European Journal of Heart Failure, 20 (12), 1721-1731. https://doi.org/10.1002/ejhf.1292. DOI: https://doi.org/10.1002/ejhf.1292

Kappel, C., Rushton, M., Johnson, C., Aseyev, O., Small, G., Law, A., Ivars, J., & Dent, S. (2019). Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Current Oncology, 26 (3), e322-e327. https://doi.org/10.3747/co.26.4509. DOI: https://doi.org/10.3747/co.26.4509

Haaf, P., Garg, P., Messroghli, D.R., Broadbent, D.A., Greenwood, J.P., & Plein, S. (2016). Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. Journal of cardiovascular magnetic resonance: Official Journal of the Society for Cardiovascular Magnetic Resonance, 18 (1), 89. https://doi.org/10.1186/s12968-016-0308-4. DOI: https://doi.org/10.1186/s12968-016-0308-4

Cannaò, P.M., Altabella, L., Petrini, M., Alì, M., Secchi, F., & Sardanelli, F. (2016). Novel cardiac magnetic resonance biomarkers: native T1 and extracellular volume myocardial mapping. European heart journal supplements: Journal of the European Society of Cardiology, 18 (Suppl E), E64-E71. https://doi.org/10.1093/eurheartj/suw022. DOI: https://doi.org/10.1093/eurheartj/suw022

McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J.G.F., Coats, A.J.S., Crespo-Leiro, M.G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A.W., Jaarsma, T., Jankowska, E.A., Lainscak, M., … ESC Scientific Document Group (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42 (36), 3599-3726. https://doi.org/10.1093/eurheartj/ehab368. DOI: https://doi.org/10.1093/eurheartj/ehab368

Bandula, S., White, S.K., Flett, A.S., Lawrence, D., Pugliese, F., Ashworth, M.T., Punwani, S., Taylor, S.A., & Moon, J.C. (2013). Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology, 269 (2), 396-403. https://doi.org/10.1148/radiology.13130130. DOI: https://doi.org/10.1148/radiol.13130130

Schindler, T.H., Sharma, V., & Bhandiwad, A. (2021). Cardiac computed tomography-derived extracellular volume fraction in the identification of cardiotoxicity: Another emerging imaging option. International journal of cardiology. Heart & Vasculature, 34, 100806. https://doi.org/10.1016/j.ijcha.2021.100806. DOI: https://doi.org/10.1016/j.ijcha.2021.100806

Egashira, K., Sueta, D., Tomiguchi, M., Kidoh, M., Oda, S., Usuku, H., Hidaka, K., Goto-Yamaguchi, L., Sueta, A., Komorita, T., Takae, M., Oike, F., Fujisue, K., Yamamoto, E., Hanatani, S., Takashio, S., Arima, Y., Araki, S., Kaikita, K., Matsushita, K., … Tsujita, K. (2021). Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity. International journal of cardiology. Heart & Vasculature, 34, 100797. https://doi.org/10.1016/j.ijcha.2021.100797. DOI: https://doi.org/10.1016/j.ijcha.2021.100797

Orsaria, P., Caredda, E., Genova, F., Materazzo, M., Capuano, I., Vanni, G., Granai, A.V., DE Majo, A., Portarena, I., Sileri, P., Petrella, G., Palombi, L., & Buonomo, O.C. (2018). Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features. Anticancer Research, 38 (4), 2109-2117. https://doi.org/10.21873/anticanres.12451. DOI: https://doi.org/10.21873/anticanres.12451

Monti, C.B., Zanardo, M., Bosetti, T., Alì, M., De Benedictis, E., Luporini, A., Secchi, F., & Sardanelli, F. (2020). Assessment of myocardial extracellular volume on body computed tomography in breast cancer patients treated with anthracyclines. Quantitative Imaging in Medicine and Surgery, 10 (5), 934-944. https://doi.org/10.21037/qims.2020.04.05. DOI: https://doi.org/10.21037/qims.2020.04.05

Chiocchi, M., Cerocchi, M., Di Tosto, F., Rosenfeld, R., Pasqualetto, M., Vanni, G., De Stasio, V., Pugliese, L., Di Donna, C., Idone, G., Muscoli, S., Portarena, I., Roselli, M., Garaci, F., & Floris, R. (2023). Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab. Journal of Personalized Medicine, 13 (2), 199. https://doi.org/10.3390/jpm13020199. DOI: https://doi.org/10.3390/jpm13020199

Jordan, J.H., Vasu, S., Morgan, T.M., D'Agostino, R.B., Jr, Meléndez, G.C., Hamilton, C.A., Arai, A.E., Liu, S., Liu, C.Y., Lima, J.A., Bluemke, D.A., Burke, G.L., & Hundley, W.G. (2016). Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Circulation. Cardiovascular imaging, 9(8), e004325. https://doi.org/10.1161/CIRCIMAGING.115.004325. DOI: https://doi.org/10.1161/CIRCIMAGING.115.004325

Ferreira de Souza, T., Quinaglia A C Silva, T., Osorio Costa, F., Shah, R., Neilan, T.G., Velloso, L., Nadruz, W., Brenelli, F., Sposito, A.C., Matos-Souza, J.R., Cendes, F., Coelho, O.R., Jerosch-Herold, M., & Coelho-Filho, O. R. (2018). Anthracycline Therapy is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease. JACC. Cardiovascular Imaging, 11 (8), 1045-1055. https://doi.org/10.1016/j.jcmg.2018.05.012. DOI: https://doi.org/10.1016/j.jcmg.2018.05.012

Naresh, N.K., Misener, S., Zhang, Z., Yang, C., Ruh, A., Bertolino, N., Epstein, F.H., Collins, J.D., Markl, M., Procissi, D., Carr, J.C., & Allen, B.A. (2020). Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity. NMR in Biomedicine, 33 (9), e4327. https://doi.org/10.1002/nbm.4327. DOI: https://doi.org/10.1002/nbm.4327

Voronkov, L.G., Berezin, O.E., Zharinova, V.Yu., Zhebel, V.M., Koval, O.A., Rudyk, Yu.S., Parkhomenko, O.M., & Tseluiko V.Y. (2019) Biological markers and their application in heart failure. Consensus of the All-Ukrainian Association of Cardiologists of Ukraine, the All-Ukrainian Association of Heart Failure Specialists and the Ukrainian Association of Emergency Cardiology Specialists. Ukrainian Journal of Cardiology, 26 (2), 11-22. URL: https://ucardioj.com.ua/index.php/UJC/article/view/168 [in Ukrainian].

Demissei, B.G., Hubbard, R.A., Zhang, L., Smith, A.M., Sheline, K., McDonald, C., Narayan, V., Domchek, S.M., DeMichele, A., Shah, P., Clark, A. S., Fox, K., Matro, J., Bradbury, A.R., Knollman, H., Getz, K.D., Armenian, S.H., Januzzi, J.L., Tang, W.H. W., Liu, P., … Ky, B. (2020). Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association, 9 (2), e014708. https://doi.org/10.1161/JAHA.119.014708. DOI: https://doi.org/10.1161/JAHA.119.014708

Kang, Y., Xu, X., Cheng, L., Li, L., Sun, M., Chen, H., Pan, C., & Shu, X. (2014). Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. European Journal of Heart Failure, 16 (3), 300-308. https://doi.org/10.1002/ejhf.8. DOI: https://doi.org/10.1002/ejhf.8

Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., & Cipolla, C.M. (2004). Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109 (22), 2749-2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC. DOI: https://doi.org/10.1161/01.CIR.0000130926.51766.CC

Popat, J., Rivero, A., Pratap, P., & Guglin, M. (2013). What is causing extremely elevated amino terminal brain natriuretic peptide in cancer patients?. Congestive Heart Failure, 19 (3), 143-148. https://doi.org/10.1111/chf.12018. DOI: https://doi.org/10.1111/chf.12018

Lyon, A.R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C.G., Moslehi, J.J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., Neilan, T.G., … Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 22 (11), 1945-1960. https://doi.org/10.1002/ejhf.1920. DOI: https://doi.org/10.1002/ejhf.2017

Radulescu, L., Avram, L., Buzdugan, E., Crisan, D., Grosu, A., Grapa, C., Stoicescu, L., Donca, V., Crisan, S., Militaru, V., Buzoianu, A., & Radulescu, D. (2022). Basic cardiovascular risk assessment in naïve patients with colon cancer. Experimental and Therapeutic Medicine, 23 (5), 318. https://doi.org/10.3892/etm.2022.11247. DOI: https://doi.org/10.3892/etm.2022.11247

Downloads

Published

2023-04-09

How to Cite

UGLYAR, T. Y., KARASHIVSKA, O. S., & NITEFOR, L. V. (2023). Cardiotoxic manifestations of chemotherapy of malignant tumors: pathogenesis and diagnosis. Hospital Surgery. Journal Named by L.Ya. Kovalchuk, (3), 119–127. https://doi.org/10.11603/2414-4533.2023.3.14159

Issue

No. 3 (2023)

Section

REVIEWS

License

Copyright (c) 2023 Т. Ю. УГЛЯР, О. С. КАРАШІВСЬКА, Л. В. НІТЕФОР

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).